KRAS and cancer: Our results strongly suggest that a single KRAS mutational status determination at the diagnosis is nor correct neither useful because cancer clonal heterogeneity can determine a change of the mutational status over the space (in different sites of disease localization) and time, as already suggested by other researchers (4, 7, 8).